Introduction {#s1}
============

Many microorganisms produce multiple secondary metabolites with diverse chemical properties and ecological functions that contribute to the fitness of the producing organism in natural environments ([@bib13]; [@bib36], [@bib47]). The biosynthesis of different secondary metabolites by a microorganism is often coordinated ([@bib6]; [@bib48]; [@bib17]; [@bib49]; [@bib8]; [@bib11]). Co-regulation of different secondary metabolites is thought to be selected during microbial evolution because it confers competitive advantages to the producing organism in microbial interactions ([@bib9]).

Among the secondary metabolites, antibiotics are particularly intriguing because of their roles in both cooperative and competitive interactions among microorganisms in natural habitats ([@bib51]; [@bib42]). This study focuses on 2,4-diacetylphloroglucinol (DAPG) and pyoluteorin, two broad-spectrum antibiotics with toxicity against fungi, bacteria, oomycetes and plants ([@bib37]; [@bib22]). Certain strains of *Pseudomonas* spp. produce DAPG but not pyoluteorin ([@bib29]) and some strains of *Pseudomonas aeruginosa* produce pyoluteorin but not DAPG ([@bib37]). To date, only a subset of strains of the species *Pseudomonas protegens* are known to produce both compounds ([@bib29]). Among these DAPG- and pyoluteorin-producing strains is the soil bacterium *P. protegens* Pf-5. In the genome of Pf-5, genes for DAPG and pyoluteorin biosynthesis are present in two different gene clusters ([Figure 1A and C](#fig1){ref-type="fig"}) separated by 3.7-megabases ([@bib38]). The biosynthetic substrates and intermediates of the two pathways are distinct ([Figure 1B and D](#fig1){ref-type="fig"}). DAPG biosynthesis begins with synthesis of phloroglucinol (PG) from three molecules of malonyl-CoA by the type III polyketide synthase PhlD ([@bib1]). PG is then acetylated through the action of PhlABC to form DAPG ([@bib3]). Pyoluteorin biosynthesis begins with activation of L-proline by the L-prolyl-AMP ligase PltF, and attachment to the peptidyl-carrier protein PltL ([@bib46]). The Pro-*S*-PltL intermediate is oxidized by PltE and chlorinated by PltA to yield 4,5-dichloropyrrolyl-*S*-PltL ([@bib46]; [@bib12]). The dichloropyrrole is extended by the type I polyketide synthase PltBC followed by release and formation of the resorcinol, presumably catalyzed by PltG to yield pyoluteorin ([@bib35], [@bib34]).10.7554/eLife.22835.003Figure 1.Biosynthetic gene clusters for 2,4-diacetylphloroglucinol (DAPG) (**A**), and pyoluteorin (**C**), the proposed biosynthetic pathways of DAPG (**B**) and pyoluteorin (**D**) of *P. protegens* Pf-5, and the GFP reporter constructs (**E, F, G**) used in this work.Arrows represent gene location and orientation in the biosynthetic gene clusters, and are colored according to their functions. The open arrow in (**E**) indicates that *pltR* is not included in the pL-gfp construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.003](10.7554/eLife.22835.003)

Despite the independent biochemical and genetic determinants for their biosynthesis, production of DAPG and pyoluteorin by *P. protegens* is tightly coordinated. Mutations in pyoluteorin biosynthetic genes result in loss of pyoluteorin production along with overproduction of DAPG ([@bib7]; [@bib41]), and addition of pyoluteorin to bacterial cultures represses the expression of certain DAPG biosynthetic genes and the production of DAPG ([@bib43]; [@bib2]). Conversely, PG, an intermediate in DAPG biosynthesis, has a concentration-dependent influence on expression of pyoluteorin biosynthetic genes and production of pyoluteorin: nanomolar concentrations of PG are required for pyoluteorin production but micromolar concentrations of PG repress pyoluteorin production ([@bib24]; [@bib10]).

The essential role of PG in pyoluteorin production became evident when we discovered that a *phlD* mutant, which lacks the type III polyketide synthase PhlD responsible for PG biosynthesis, produces neither pyoluteorin nor DAPG. The *phlD* mutant can be complemented for pyoluteorin production by addition of nanomolar concentrations of PG to the culture medium ([@bib24]). Furthermore, addition of nanomolar concentrations of PG induces expression of pyoluteorin biosynthetic genes ([@bib10]), indicating that the influence of PG on pyoluteorin production is mediated through gene regulation. Pyoluteorin itself also induces expression of pyoluteorin biosynthetic genes ([@bib7]; [@bib28]). The pyoluteorin biosynthetic genes are expressed under the positive control of PltR ([@bib7]) ([Figure 1](#fig1){ref-type="fig"}), a transcriptional regulator belonging to the LysR family. Both PG and pyoluteorin are known to induce PltR-mediated transcription of pyoluteorin biosynthetic genes, but the relative importance of the two small molecules in inducing gene expression has not been evaluated.

The metabolic co-regulation between DAPG and PLT biosynthetic pathways differs from known examples of metabolic co-regulation between secondary metabolic pathways, which can be classified into four types based on the underlying mechanisms. The first type of co-regulation involves one or more intermediates that are shared by different biosynthetic pathways ([@bib49]; [@bib8]). The second type results when a single enzyme is shared by different pathways ([@bib27]; [@bib48]). The third type of co-regulation is mediated through functionally redundant enzymes present in different pathways ([@bib26]). The fourth type occurs when the biosynthetic genes for two pathways are controlled by the same 'pathway-specific' regulator ([@bib40]; [@bib4]). Overall these mechanisms of metabolic co-regulation involve a shared biosynthetic intermediate, enzymatic activity, or regulator, but none of these features is shared by the DAPG and pyoluteorin pathways ([Figure 1](#fig1){ref-type="fig"}).

Here, we describe a mechanism of metabolic co-regulation that is distinct from all described previously. Our results show that PG, an intermediate in DAPG biosynthesis, is transformed by a halogenase encoded in the pyoluteorin gene cluster into chlorinated derivatives that function as cell-cell communication signals inducing expression of pyoluteorin biosynthetic genes. Our work reveals a new mechanism of co-regulation between two secondary metabolic pathways, which is mediated by an intermediate in one pathway that is converted into signals that activate the second pathway.

Results {#s2}
=======

PG is required for PltR-mediated activation of *pltL* expression {#s2-1}
----------------------------------------------------------------

To determine the differences between the regulatory roles of PG and pyoluteorin in the production of pyoluteorin, we evaluated the effects of both metabolites on expression of the pyoluteorin biosynthetic gene *pltL* using pL-gfp ([Figure 1E](#fig1){ref-type="fig"}), a reporter construct containing a transcriptional fusion of the promoter of *pltL* to a promoterless *gfp* ([@bib50]). GFP expressed from pL-gfp was monitored in a Δ*pltA*Δ*phlD* double mutant grown in a medium amended with each of the two metabolites alone or in combination ([Figure 2](#fig2){ref-type="fig"}). In the non-amended medium, and relative to wild-type Pf-5, GFP expression was significantly lower in the Δ*pltA*Δ*phlD* mutant (*p*=2.76E-4), indicating only background expression of *pltL*. This result was expected because of the deletion of *pltA* and *phlD*, which encode enzymes for biosynthesis of pyoluteorin and PG, respectively ([Figure 1](#fig1){ref-type="fig"}); both pyoluteorin and PG are known to induce expression of pyoluteorin biosynthetic genes ([@bib7]; [@bib10]). In the medium amended with 10 nM PG, GFP expression of the Δ*pltA*Δ*phlD* mutant increased nearly tenfold relative to expression levels in non-amended medium, indicating induction of *pltL*. In contrast, addition of 100 nM pyoluteorin failed to alter GFP expression by the Δ*pltA*Δ*phlD* mutant. However, when both pyoluteorin and PG were added, the GFP expression was significantly higher than under treatment with PG alone (*p*=1.44E-4). Therefore, pyoluteorin was not required for *pltL* expression but further induced *pltL* expression in the presence of PG. As expected based on the necessity of PltR for expression of the pyoluteorin biosynthetic genes ([@bib7]; [@bib28]), *pltR* was required for expression of *pltL* and the presence of PG could not restore *pltL* expression in a Δ*pltA*Δ*phlD*Δ*pltR* mutant ([Figure 2](#fig2){ref-type="fig"}). These results indicated that PG, not pyoluteorin, is required for PltR-mediated activation of *pltL*.10.7554/eLife.22835.004Figure 2.Effect of phloroglucinol (PG) and pyoluteorin on expression of *pltL::gfp* in *P. protegens* Pf-5.Pf-5 wild-type and derivatives containing pL-gfp were treated with PG (10 nM) and/or pyoluteorin (100 nM), as indicated. Expression levels of *pltL::gfp* were measured and recorded as relative GFP (fluorescence of GFP divided by OD~600~). Letters above columns indicate treatments significantly different from one another, as determined by ANOVA analysis (*p*\<0.05). Data are means of at least three biological replicates from a representative experiment repeated three times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.004](10.7554/eLife.22835.004)10.7554/eLife.22835.005Figure 2---source data 1.Expression of *pltL::gfp* by Pf-5 wild-type (WT) and its derivatives in response to PG and/or pyoluteorin.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.005](10.7554/eLife.22835.005)

PG activates expression of *pltL* indirectly {#s2-2}
--------------------------------------------

To test whether PG directly or indirectly regulates expression of the pyoluteorin biosynthetic genes, we assessed the effect of PG on expression of *pltL* in *P. fluorescens* SBW25. Like *P. protegens* Pf-5, strain SBW25 is a member of the *P. fluorescens* group but, unlike Pf-5, SBW25 has neither the *phl* gene cluster nor the *plt* gene cluster ([@bib44]). Because SBW25 does not have *pltR*, which is required for *pltL* expression, we made the transcriptional reporter construct pRL-gfp, which contains *pltR* and the intergenic region between *pltR* and *pltL* that includes the promoter of *pltL* fused to a promoterless *gfp* ([Figure 1F](#fig1){ref-type="fig"}). Although PG was sufficient to induce *pltL* expression in Pf-5 ([Figure 2](#fig2){ref-type="fig"}), PG failed to induce GFP expression from pRL-gfp in *P. fluorescens* SBW25 ([Figure 3A](#fig3){ref-type="fig"}) and is therefore not likely to function as a signal directly. One possible explanation for these results is that Pf-5 processes PG to another compound, which then directly induces pyoluteorin gene expression. To test this possibility, we amended SBW25 carrying pRL-gfp with culture supernatants from Pf-5 or the Δ*phlD* mutant and measured *pltL* expression. Consistent with our hypothesis, culture supernatants from Pf-5, but not the Δ*phlD* mutant, could induce GFP expression of SBW25 ([Figure 3A](#fig3){ref-type="fig"}). Therefore, we concluded that PG does not directly influence pyoluteorin gene expression. Rather, PG could be converted to a compound(s) that regulates pyoluteorin gene expression.10.7554/eLife.22835.006Figure 3.Effect of phloroglucinol (PG) and Pf-5 culture supernatants on expression of *pltL::gfp* in *P. fluorescens* SBW25 (**A, C**), and *P. protegens* Pf-5 (**B**).(**A**) Expression of *pltL::gfp* in SBW25 containing pRL-gfp. (**B**) Expression of *pltL::gfp* in wild-type (WT) Pf-5 and the Δ*phlM* mutant containing pL-gfp. (**C**) Expression of *pltL::gfp* in SBW25 containing pMRL-gfp. In each experiment, the concentration of PG is 10 nM, and the same volume of methanol was added to the bacterial cultures as a control. The supernatants of bacterial cultures were mixed with the fresh bacterial cultures at a 1:1 vol ratio to test their effects on *pltL::gfp* expression; WT-Sup, the culture supernatants of wild-type Pf-5; Δ*phlD*-Sup, the culture supernatants of a Δ*phlD* mutant. The expression levels of *pltL::gfp* were measured and recorded as relative GFP (fluorescence of GFP divided by OD~600~). Letters above columns indicate treatments significantly different from one another, as determined by ANOVA analysis (*p*\<0.05). Data are means of at least three biological replicates from a representative experiment repeated three times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.006](10.7554/eLife.22835.006)10.7554/eLife.22835.007Figure 3---source data 1.Expression of *pltL::gfp* by SBW25 and Pf-5 in response to phloroglucinol (PG) and Pf-5 culture supernatants.(**A**) Expression of *pltL::gfp* by SBW25 containing pRL-gfp. (**B**) Expression of *pltL::gfp* by Pf-5 wild-type (WT) and the Δ*pltM* mutant that contains pL-gfp. (**C**) Expression of *pltL::gfp* by SBW25 containing pMRL-gfp.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.007](10.7554/eLife.22835.007)10.7554/eLife.22835.008Figure 3---figure supplement 1.Transcriptional profiles of *pltM*, *pltR* and the other genes in the pyoluteorin gene cluster of Pf-5.Data were generated from our previous transcriptomic study ([@bib10]). The height of the black peaks indicates the expression levels of genes in the pyoluteorin gene cluster of the wild-type Pf-5 (Pf-5 combined coverage), the Δ*phlA*Δ*phlD*Δ*phlG* three-fold mutant (phlADG combined coverage), and the Δ*phlA*Δ*phlD*Δ*phlG* three-fold mutant grown in a medium containing 100 nM PG (phlADG_PG combined coverage). For the three strains/treatments, expression levels of genes are indicated in different scales to show the general expression profile of the whole gene cluster.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.008](10.7554/eLife.22835.008)10.7554/eLife.22835.009Figure 3---figure supplement 2.Production of pyoluteorin, DAPG and MAPG by *P. protegens* Pf-5 wild-type (WT), a Δ*pltM* mutant, and a *pltM*+ complemented strain.Secondary metabolites were extracted from bacterial cultures incubated for 24 hr in NBGly. Data are means of three biological replicates from a representative experiment repeated twice with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.009](10.7554/eLife.22835.009)10.7554/eLife.22835.010Figure 3---figure supplement 2---source data 1.Concentration of pyoluteorin, MAPG and DAPG (µM) in cultures of Pf-5 wild-type (WT) and its derivatives.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.010](10.7554/eLife.22835.010)

*pltM* is necessary and sufficient for the PltR-mediated activation of *pltL* expression by PG {#s2-3}
----------------------------------------------------------------------------------------------

We then attempted to identify a mechanism by which Pf-5 could convert PG to the compound(s) that directly induces pyoluteorin gene expression. Within the *plt* gene cluster of Pf-5, *pltM* attracted our attention because of its proximity to *pltR* ([Figure 1C](#fig1){ref-type="fig"}). *pltM* and *pltR* are predicted to form a bicistronic operon because of a four-base overlap between the 5' end of *pltM* and the 3' terminus of *pltR* ([@bib38]). Moreover, *pltM* and *pltR* share similar transcriptional profiles, which differ from those of other genes in the *plt* gene cluster ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; [@bib10]). PltM is a putative FADH~2~-dependent halogenase and is required for pyoluteorin production: a *pltM* insertion mutant is deficient in the production of pyoluteorin ([@bib34]). The reason why PltM is required is unclear because the *plt* gene cluster encodes another FADH~2~-dependent halogenase PltA that catalyzes the addition of both chlorines to the pyrrole moiety to form pyoluteorin ([@bib12]). Therefore, we hypothesized that PltM is responsible for conversion of PG into the compound(s) that induces the expression of pyoluteorin biosynthetic genes.

To avoid any concerns regarding potential polar effects of the insertion in the previously derived *pltM* mutant ([@bib34]), we generated a mutant with an in-frame deletion of *pltM* and confirmed that the Δ*pltM* mutant does not produce pyoluteorin ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Pyoluteorin production by the Δ*pltM* mutant could be complemented by a plasmid-borne copy of *pltM*, confirming that *pltM* has an essential role in pyoluteorin production.

We introduced pL-gfp into the Δ*pltM* mutant and found that the mutant expressed only background levels of GFP, indicating that expression of *pltL* was not induced in this mutant ([Figure 3B](#fig3){ref-type="fig"}). The GFP expression remained at background levels even when cells were grown in the presence of 10 nM PG. However, GFP expression of the Δ*pltM* mutant was induced by culture supernatants of Pf-5 ([Figure 3B](#fig3){ref-type="fig"}). As expected, culture supernatants of the Δ*phlD* mutant failed to induce GFP expression of the Δ*pltM* mutant containing pL-gfp. These results supported our hypothesis and indicated that wild-type Pf-5, but not the Δ*pltM* mutant, produces the compound(s) that induces the *pltL* expression.

To test whether *pltM* is sufficient for signaling in SBW25, we made a transcriptional fusion construct pMRL-gfp, which contains *pltM*, *pltR*, and the intergenic region between *pltR* and *pltL* that includes the promoter of *pltL* fused with the promoterless *gfp* ([Figure 1G](#fig1){ref-type="fig"}). Like SBW25 containing pRL-gfp, SBW25 containing pMRL-gfp had only low, background GFP expression in the non-amended medium, and higher GFP expression level in the presence of culture-supernatants from wild-type Pf-5 ([Figure 3A and C](#fig3){ref-type="fig"}). While PG failed to induce GFP expression of SBW25 containing pRL-gfp ([Figure 3A](#fig3){ref-type="fig"}), it induced GFP expression of SBW25 containing pMRL-gfp ([Figure 3C](#fig3){ref-type="fig"}). These results indicated that *pltM* is sufficient for signaling in SBW25 in the presence of PG and the regulatory gene *pltR*.

Identification of chlorinated phloroglucinols from Pf-5 cultures {#s2-4}
----------------------------------------------------------------

To identify the compound(s) that induce(s) expression of *pltL*, we extracted bacterial metabolites from cultures of the wild-type Pf-5 and the Δ*pltM* mutant, and analyzed the extracts by liquid chromatography--mass spectrometry (LCMS). This analysis revealed the presence of 2-chlorobenzene-1,3,5-triol (PG-Cl) in culture extracts of the wild-type Pf-5 but not the Δ*pltM* mutant ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We also separated the extracts of the wild-type into fractions using semi-preparatory HPLC, and assayed the fractions for signaling activity. This analysis revealed two peaks that induced *pltL* expression in SBW25 (pPL-gfp) ([Figure 4C](#fig4){ref-type="fig"}), suggesting that Pf-5 produces at least two signaling compounds.10.7554/eLife.22835.011Figure 4.Identification of the signaling metabolites from Pf-5 that induce expression of *pltL::gfp* in *P. fluorescens* SBW25 (pRL-gfp).Metabolites were extracted from wild-type (WT) Pf-5, and a phloroglucinol (PG)-fed Δ*gacA* mutant of Pf-5 carrying a plasmid that constitutively expresses *pltM *(pME6010-pltM). The extracts were fractioned into 48 fractions using semi-preparatory HPLC (no observable signal activity was detected from the last 12 fractions, data not shown). The signal activity of the fractions from both strains was tested using strain *P. fluorescens* SBW25 containing pRL-gfp (**C**). Data are means of three biological replicates, and error bars represent the standard deviation of the mean. (**A**) Mass spectra of compound eluting at 3.3 min in Fraction 21 (left) and 9 min in Fraction 26 (right) from the Δ*gacA* (pME6010-pltM) culture extracts. (**B**) Comparisons between the signal compounds identified in Pf-5 cultures to synthesized PG-Cl and PG-Cl~2~, which elute at 3.3 and 9 min, respectively, as indicated by the dashed arrows. BPC, base peak chromatogram; EIC, extracted ion chromatogram; Std, synthesized standards. The *m/z* used for EIC analysis of PG-Cl and PG-Cl~2~ are also shown.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.011](10.7554/eLife.22835.011)10.7554/eLife.22835.012Figure 4---figure supplement 1.LCMS analysis of crude extracts of bacterial metabolites from cultures of wild-type Pf-5 (**A**) and Δ*pltM* mutant (**B**).BPC, base peak chromatogram (top); EIC, extracted ion chromatogram (158.8--159.0 m/z, middle); Std, PG-Cl standard (bottom).**DOI:** [http://dx.doi.org/10.7554/eLife.22835.012](10.7554/eLife.22835.012)

To obtain sufficient levels of signaling molecules for chemical analysis, we constructed a derivative strain of Pf-5 that overproduced the signaling compounds. This overproducing strain is a Δ*gacA* mutant of Pf-5 carrying plasmid pME6010-pltM, which expresses *pltM* from a constitutive kanamycin-resistance promoter (Pk) ([@bib15]). The Δ*gacA* mutant does not produce many of the secondary metabolites produced by wild-type Pf-5 ([@bib14]) and thus its use helps to reduce the noise in LCMS analysis. The strain Δ*gacA* (pME6010-pltM) was cultured in a medium amended with PG, and bacterial metabolites from the cultures were extracted and assayed for signal activity using SBW25 (pPL-gfp), as described for the wild-type Pf-5 above. As in the extract of wild-type Pf-5, two peaks in the extract of the Δ*gacA* (pME6010-pltM) strain, spread across six fractions (fractions 19--21, 24--26), showed signal activity ([Figure 4C](#fig4){ref-type="fig"}). LCMS analysis revealed compounds with protonated ions consistent with PG-Cl in fraction 21 (obs. 158.9847, calc. 158.9854, 4.4 ppm error) and 2,4-dichlorobenzene-1,3,5-triol (PG-Cl~2~) in fraction 26 (obs. 192.9474, calc. 192.9465, 4.7 ppm error) ([Figure 4A](#fig4){ref-type="fig"}). The identities of PG-Cl and PG-Cl~2~ partially purified from the culture extracts were confirmed by comparing them with the synthesized authentic compounds ([Figure 4B](#fig4){ref-type="fig"}).

PG-Cl, a molecule with previously undescribed biological activity, has been isolated from the red alga *Rhabdoina verticillata* ([@bib5]). To our knowledge, PG-Cl~2~ has not been previously reported. The structures of these two chlorinated phloroglucinol derivatives are consistent with the expected products of a reaction catalyzed by PltM, an FADH~2~-dependent halogenase.

PltM converts PG in vitro into chlorinated phloroglucinols that activate the expression of *pltL* {#s2-5}
-------------------------------------------------------------------------------------------------

To determine the catalytic activity of PltM, we characterized the products generated in vitro from PG by PltM. As a putative FADH~2~-dependent halogenase, PltM is predicted to require a flavin reductase for catalysis ([@bib34]), but no putative flavin reductase is encoded in the *plt* gene cluster ([Figure 1C](#fig1){ref-type="fig"}). Therefore, the previously characterized NAD(P)H-dependent flavin reductase SsuE from *E. coli* ([@bib23]) was purified and used here. The results showed that, in the presence of co-factors and flavin reductase, PltM converted PG into a compound(s) that activated *pltL* expression, as determined from GFP expression of SBW25 containing pRL-gfp ([Figure 5](#fig5){ref-type="fig"}). Furthermore, LCMS analysis showed that both PG-Cl and PG-Cl~2~ were present in the in vitro reaction containing PltM, but not in the reaction without PltM, based on comparisons with the authentic standards ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).10.7554/eLife.22835.013Figure 5.Effect of extracts from in vitro catalyzed reactions on expression of *pltL::gfp* in *P. fluorescens* SBW25.PltM was purified from *E. coli* and incubated with a mixture of flavin reductase SsuE, substrate PG, and co-factors FAD and NADPH. The effect of extracted compounds from the reactions was tested using *P. fluorescens* SBW25 containing pRL-gfp. \"+" and \"--" indicate the presence or absence of the component in the reactions, respectively. The expression level of *pltL::gfp* was measured and recorded as relative GFP (fluorescence of GFP divided by OD~600~). Letters above columns indicate treatments significantly different from one another, as determined by ANOVA analysis (*p*\<0.05). Data are means of at least three biological replicates from a representative experiment repeated twice with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.013](10.7554/eLife.22835.013)10.7554/eLife.22835.014Figure 5---source data 1.Expression of *pltL::gfp* by SBW25 containing pRL-gfp in response to extracts from in vitro reactions.EM-1\# to −6\# refers to extracts from each in vitro reaction with the components shown.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.014](10.7554/eLife.22835.014)10.7554/eLife.22835.015Figure 5---figure supplement 1.LCMS analysis of PltM reaction mixtures.(**A**) Base peak chromatogram (BPC) for the complete reaction mixture containing PG, FAD, NADH, SsuE, and PltM in Tris buffer (top); BPC for the reaction mixture lacking PltM (containing PG, FADH, NADH, and SsuE in Tris buffer) (middle); BPC for chlorinated phloroglucinol standards, PG-Cl, PG-Cl~2~, and PG-Cl~3~ elute at 12.5, 17.2, and 18.8 min, respectively. A peak observed only in the complete reaction mixture is highlighted in yellow and has an identical retention time to that of the PG-Cl standard. (**B**) Extracted ion chromatograms (EIC) for the complete reaction mixture (red) or the reaction mixture lacking PltM (black). Top panel, EIC 158.8--159.0 (PG-Cl); second panel, EIC 192.8--193.0 (PG-Cl~2~); third panel, EIC 226.8--227.0 (PG-Cl~3~). Bottom panel, BPC for PG-Cl, PG-Cl~2~, and PG-Cl~3~ standards, which elute at 12.5, 17.2, and 18.8 min, respectively. (**C**) Mass spectrum generated by the peak observed in the EIC 158.8--159.0 of the complete PltM reaction eluting at 12.5 min (PG-Cl calc. \[M-H\]^−^ 158.9854, 1.3 ppm error). (**D**) Mass spectrum generated by the peak observed in the EIC 192.8--193.0 of the complete PltM reaction eluting at 17.2 min (PG-Cl~2~ calc. \[M-H\]^−^ 192.9465, 2.6 ppm error).**DOI:** [http://dx.doi.org/10.7554/eLife.22835.015](10.7554/eLife.22835.015)10.7554/eLife.22835.016Figure 5---figure supplement 2.Effect of different compounds that have structures similar to phloroglucinol (PG) on the expression of *pltL::gfp* in *P. fluorescens* SBW25.Resorcinol, triclosan, and 2,4-D (2,4-Dichlorophenoxyacetic acid), which have structures similar to PG, were used to test the substrate specificity of PltM. Different concentrations of these compounds were added to cultures of SBW25 containing reporter plasmid pMRL-gfp in NBGly broth. PG was used as a positive control in this experiment. The same volume of methanol was added to the cultures (Me) as a negative control. The expression level of *pltL::gfp* was monitored and recorded as relative GFP, which was calculated by GFP divided by OD~600~. Differing letters above the columns indicate treatments significantly different from one another, as determined by ANOVA analysis (*p*\<0.05). Compared with PG, no comparable signaling effects of the tested compounds were observed. Data are means of three biological replicates from a representative experiment repeated two times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.016](10.7554/eLife.22835.016)10.7554/eLife.22835.017Figure 5---figure supplement 2---source data 1.Expression of *pltL::gfp* by SBW25 containing pMRL-gfp in response to PG and compounds with similar structures to PG.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.017](10.7554/eLife.22835.017)

By evaluating a range of compounds related to PG as possible precursors, we also demonstrated that PltM exhibits a high degree of substrate specificity ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). These in vitro data, combined with the genetic data above, demonstrate that *pltM* is necessary and sufficient for converting PG into PG-Cl and PG-Cl~2~, which induce *pltL* expression.

Chlorinated phloroglucinols induce the PltR-mediated activation of *pltL::gfp* and production of pyoluteorin {#s2-6}
------------------------------------------------------------------------------------------------------------

We then set out to test the function of PG-Cl or PG-Cl~2~ in pyoluteorin biosynthesis of Pf-5. Addition of synthesized PG-Cl or PG-Cl~2~ to cultures induced, in a concentration-dependent manner, expression of *pltL* ([Figure 6A and B](#fig6){ref-type="fig"}) and pyoluteorin production ([Figure 6C and D](#fig6){ref-type="fig"}) by the Δ*pltM* mutant of Pf-5. The minimum concentration of PG-Cl~2~ that induced the expression of *pltL* or production of pyoluteorin was 0.01 μM, which is 100-fold less than that observed for PG-Cl. These results suggest that PG-Cl~2~ is a more potent signaling compound than PG-Cl. Additionally, there is evidence of toxicity: above 0.1 µM PG-Cl~2~, growth of *P. protegens* Pf-5 decreased ([Figure 6B](#fig6){ref-type="fig"}). PG-Cl was also toxic to Pf-5, but only at concentrations of 10 μM or higher. Similarly, PG-Cl and PG-Cl~2~ showed inhibitory effects on the growth of *P. fluorescens* strain SBW25 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Induction of *pltL* expression and pyoluteorin production by both PG-Cl and PG-Cl~2~ required *pltR* ([Figure 6---figure supplements 2](#fig6s2){ref-type="fig"} and [3](#fig6s3){ref-type="fig"}). This is as expected because PltR is known to be the transcriptional inducer of pyoluteorin biosynthetic genes ([@bib7]; [@bib28]).10.7554/eLife.22835.018Figure 6.Influence of PG-Cl (left) and PG-Cl~2~ (right) on expression of *pltL::gfp* (**A, B**) and production of pyoluteorin (**C, D**) in the Δ*pltM* mutant of *P. protegens* Pf-5.The Δ*pltM* mutant was cultured in NBGly amended with increasing concentrations of PG-Cl and PG-Cl~2~. To test the regulatory effects of PG-Cl and PG-Cl~2~ on expression of pyoluteorin biosynthetic genes, GFP activity was determined from the Δ*pltM* mutant containing pL-gfp 20 hr after inoculation (**A, B**). The OD~600~ value of bacterial cultures (24 hr after inoculation) was measured to show the influence of PG-Cl and PG-Cl~2~ on the bacterial growth (**A, B**). The bacterial cultures were extracted 24 hr after inoculation and production of pyoluteorin, MAPG and DAPG were quantified (**C, D**). Letters above the symbols indicate treatments significantly different from one another, as determined by ANOVA analysis (*p*\<0.05). Data are means of at least three biological replicates from a representative experiment repeated twice with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.018](10.7554/eLife.22835.018)10.7554/eLife.22835.019Figure 6---source data 1.Expression of *pltL::gfp* and production of pyoluteorin by the Δ*pltM* mutant of Pf-5 in response to chlorinated phloroglucinols.The production of MAPG and DAPG is also shown.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.019](10.7554/eLife.22835.019)10.7554/eLife.22835.020Figure 6---figure supplement 1.Effect of PG-Cl and PG-Cl~2~ on growth of *P. fluorescens* SBW25.Strain SBW25 was cultured in NBGly amended with PG-Cl and PG-Cl~2~. The final concentrations of the compounds used in the cultures are indicated. Bacterial growth was recorded by measuring OD~600~ value of the cultures at 20 hr. Data are means of three biological replicates, and error bars represent the standard deviation of the mean. The experiment was done at least twice with similar results and results from one experiment are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.020](10.7554/eLife.22835.020)10.7554/eLife.22835.021Figure 6---figure supplement 1---source data 1.Toxicity of PG-Cl and PG-Cl~2~ to *P. fluorescens* SBW25.PG-Cl and PG-Cl~2~ were tested at different concentrations as indicated. 0 means methanol was added to the cultures as a control.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.021](10.7554/eLife.22835.021)10.7554/eLife.22835.022Figure 6---figure supplement 2.Effect of PG-Cl and PG-Cl~2~ on expression of *pltL::gfp* (**A**) and production of pyoluteorin (**B**) in the Δ*pltM*Δ*phlD* mutant and the Δ*pltM*Δ*pltR* mutant of *P. protegens* Pf-5.The Δ*pltM*Δ*phlD* mutant and the Δ*pltM*Δ*pltR* mutant were cultured in NBGly broth with addition of PG-Cl and PG-Cl~2~. The final concentrations of the compounds (µM) used in the cultures are shown. (**A**) To test the regulatory effects of PG-Cl and PG-Cl~2~ on expression of pyoluteorin biosynthetic genes, the mutants containing pL-gfp were used. The expression level of *pltL::gfp* was monitored and recorded as relative GFP, which was calculated as GFP divided by OD~600~. (**B**) To test the regulatory effect of PG-Cl and PG-Cl~2~ on the production of pyoluteorin, secondary metabolites were extracted from the cultures and analyzed by HPLC. Data are means of three biological replicates from a representative experiment repeated two times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.022](10.7554/eLife.22835.022)10.7554/eLife.22835.023Figure 6---figure supplement 2---source data 1.Expression of *pltL::gfp* and the production of pyoluteorin by Pf-5 wild-type (WT) and its derivatives in response to chlorinated phloroglucinols.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.023](10.7554/eLife.22835.023)10.7554/eLife.22835.024Figure 6---figure supplement 3.Effect of PG-Cl and PG-Cl~2~ on the expression of *pltL*::*gfp* in *P. fluorescens* SBW25.SBW25 strains containing reporter construct pRL-gfp (left of dotted line) and pL-gfp (right of dotted line) were cultured in NBGly amended with PG-Cl and PG-Cl~2~. The final concentrations of the compounds (µM) used in the cultures are indicated. The same volume of methanol was added to the cultures serving as negative controls (Methanol). The expression level of *pltL::gfp* was monitored and recorded as relative GFP, which was calculated as GFP divided by OD~600~. Data are means of three biological replicates from a representative experiment repeated three times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.024](10.7554/eLife.22835.024)10.7554/eLife.22835.025Figure 6---figure supplement 3---source data 1.Expression of *pltL::gfp* by SBW25 containing pL-gfp or pRL-gfp in response to chlorinated phloroglucinols.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.025](10.7554/eLife.22835.025)

PG-Cl and PG-Cl~2~ induced pyoluteorin production concurrently with decreased monoacetylphloroglucinol (MAPG) and DAPG production by the Δ*pltM* mutant ([Figure 6C and D](#fig6){ref-type="fig"}). This result is consistent with the known co-regulation between the pyoluteorin and DAPG biosynthetic pathways ([@bib7]).

PG-Cl and PG-Cl~2~ function in cell-cell communication and influence antibiosis of Pf-5 {#s2-7}
---------------------------------------------------------------------------------------

DAPG and pyoluteorin are known signals produced by distinct biosynthetic pathways with described roles in intercellular communication of *P. protegens* ([@bib43]; [@bib7]). Several observations suggested that PG-Cl and PG-Cl~2~ also function as cell-cell communication signals: (1) they are released by the bacterial cell ([Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}); (2) they can be taken up by the bacterial cell ([Figure 6](#fig6){ref-type="fig"}); (3) they regulate gene expression at the transcriptional level and affect the output (antibiotic production) of the cell ([Figure 6](#fig6){ref-type="fig"}); (4) their production varies with the growth stage of the bacterial cultures ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}); and (5) their regulatory activities rely on a transcriptional regulator, PltR ([Figure 6---figure supplements 2](#fig6s2){ref-type="fig"} and [3](#fig6s3){ref-type="fig"}). These results, combined with our previous finding that PG can function as a chemical messenger between cells of *P. protegens* ([@bib10]), collectively support the model depicted in [Figure 7A](#fig7){ref-type="fig"}, in which PG-Cl and PG-Cl~2~ can be synthesized from PG by bacterial cells, released into the environment and taken up by neighboring cells to induce expression of pyoluteorin biosynthetic genes and produce pyoluteorin.10.7554/eLife.22835.026Figure 7.PG-Cl and PG-Cl~2~ function as cell-cell communication signals of *P. protegens* Pf-5.(**A**) Proposed cell-cell communication model. Cell \[1\] (Δ*phlA*Δ*pltM*) produces phloroglucinol (PG) and releases it into the environment. PG is taken up by cell \[2\] (*ΔphlAΔphlDΔpltA*) and converted into PG-Cl and PG-Cl~2~, which are secreted into the environment. PG-Cl and PG-Cl~2~ are taken up by cell \[1\] and induce expression of pyoluteorin biosynthetic genes and production of pyoluteorin by cell \[1\]. The *plt* gene cluster is shown. Red font indicates that the gene was deleted. (**B**) GFP expression from the pure- and co-culture of the Δ*phlA*Δ*pltM* mutant containing pL-gfp and the Δ*phlA*Δ*phlD*Δ*pltA* mutant containing pL-gfp on NAGly plate. (**C**) Antibiosis of the pure- and co-culture of the Δ*phlA*Δ*pltM* mutant and Δ*phlA*Δ*phlD*Δ*pltA* mutant against growth of *Erwinia amylovora* on a NAGly plate. The co-culture was prepared by mixing the two mutants 1:1 and spotting on the plate. The experiment was repeated at least twice, with similar results.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.026](10.7554/eLife.22835.026)10.7554/eLife.22835.027Figure 7---figure supplement 1.Levels of signaling compounds in cultures of *P. protegens* Pf-5 of different ages.Relative levels of signaling compounds that induce *pltL* expression were determined from extracts of Pf-5 culture supernatants by assessing GFP expressed by *P. fluorescens* SBW25 containing the reporter construct pRL-gfp. Cultures of wild-type Pf-5 were grown in 5 ml NBGly for different times, as indicated. Data are means of three biological replicates from a representative experiment repeated three times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.027](10.7554/eLife.22835.027)10.7554/eLife.22835.028Figure 7---figure supplement 1---source data 1.Expression of *pltL::gfp* by SBW25 in response to extracts of wild-type Pf-5 cultures.Pf-5 wild-type was cultured for different times, as indicated. The culture extracts were tested by SBW25 containing pRL-gfp.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.028](10.7554/eLife.22835.028)10.7554/eLife.22835.029Figure 7---figure supplement 2.Toxicity of pyoluteorin (**A**) and DAPG (**B**) to the plant pathogen *Erwinia amylovora*.*Erwinia amylovora* was cultured in NBGly broth for 24 hr in a 96-well plate with or without the tested compounds. The final concentrations of the tested compounds are indicated. The growth of the bacteria was monitored by measuring the value of OD~600~ of the bacterial cultures. Me, negative control composed of a culture amended with the same volume of methanol used in cultures amended with pyoluteorin or DAPG. Data are means of three biological replicates from a representative experiment repeated two times with similar results, and error bars represent the standard deviation of the mean.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.029](10.7554/eLife.22835.029)10.7554/eLife.22835.030Figure 7---figure supplement 2---source data 1.Growth of *Erwinia amylovora* in response to pyoluteorin and DAPG.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.030](10.7554/eLife.22835.030)

We used Δ*phlA*Δ*pltM* and Δ*phlA*Δ*phlD*Δ*pltA* mutants of Pf-5 to test the model. Both mutants expressed the pyoluteorin biosynthetic gene *pltL* at low levels as indicated by low GFP expression from pL-gfp ([Table 1](#tbl1){ref-type="table"}, [Figure 7B](#fig7){ref-type="fig"}). The Δ*phlA*Δ*pltM* mutant can produce PG but cannot convert it into PG-Cl or PG-Cl~2~, because of the deletion of *pltM*. Adding PG-Cl or PG-Cl~2~ to the Δ*phlA*Δ*pltM* mutant culture led to induced expression of *pltL* ([Table 1](#tbl1){ref-type="table"}), indicating that this mutant could respond to the signals. The Δ*phlA*Δ*phlD*Δ*pltA* mutant could not produce PG because of the deletion of *phlD*, but still has the capability to convert PG into PG-Cl and PG-Cl~2~: adding PG to the culture led to increased expression of *pltL* ([Table 1](#tbl1){ref-type="table"}). Neither mutant could produce pyoluteorin when grown in pure culture, because of the *phlD* and *pltA* mutations in the Δ*phlA*Δ*phlD*Δ*pltA* mutant and the *pltM* mutation in the Δ*phlA*Δ*pltM* mutant. In contrast, pyoluteorin was produced when the two mutants were grown in co-culture ([Table 1](#tbl1){ref-type="table"}). Consistently, both mutants showed increased expression of *pltL* in the co-culture compared with the mutants grown in pure culture ([Table 1](#tbl1){ref-type="table"}, [Figure 7B](#fig7){ref-type="fig"}). These results support our model ([Figure 7A](#fig7){ref-type="fig"}) that PG produced by the Δ*phlA*Δ*pltM* mutant could be converted into PG-Cl and PG-Cl~2~ by co-cultured cells of the Δ*phlA*Δ*phlD*Δ*pltA* mutant; PG-Cl and PG-Cl~2~ could then be used by the Δ*phlA*Δ*pltM* mutant to induce production of pyoluteorin. As expected, the co-culture, but not the pure cultures, of the two mutants inhibited the growth of *E. amylovora* ([Figure 7C](#fig7){ref-type="fig"}), a plant pathogenic bacterium that is sensitive to pyoluteorin ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). It is worthy to note that neither mutant produces DAPG ([Table 1](#tbl1){ref-type="table"}) because of the deletion of *phlA*, a structural gene required for DAPG biosynthesis ([Figure 1A and B](#fig1){ref-type="fig"}), so DAPG production did not obscure the influence of pyoluteorin production on antibiosis.10.7554/eLife.22835.031Table 1.Concentrations of DAPG, pyoluteorin, and expression of *pltL*::*gfp* in pure cultures and co-culture of the Δ*phlA*Δ*pltM* mutant and the Δ*phlA*Δ*phlD*Δ*pltA* mutant of *P. protegens* Pf-5.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.031](10.7554/eLife.22835.031)Product/expression\*Amendment^†^Bacterial cultures^‡^Δ*phlA*Δ*pltM*Δ*phlA*Δ*pltM* + Δ*phlA*Δ*phlD*Δ*pltA*Δ*phlA*Δ*phlD*Δ*pltA*PyoluteorinNoneBD6.2 ± 1.8 nmol/gBDDAPGNoneBDBDBDRelative GFPNone34.6 ± 2.3137.4 ± 3.4^§^; 214.7 ± 11.2^¶^27.6 ± 1.9PG (10 nM)37.6 ± 3.1NT133.3 ± 6.4PG-Cl (1 µM)261.0 ± 13.3NT308.6 ± 21.8PG-Cl~2~ (10 nM)128.2 ± 10.7NT268.4 ± 16.2[^1][^2][^3]

Collectively, our results support the hypothesis that PG-Cl and PG-Cl~2~ function in cell-cell communication of *P. protegens* and verify that cells of this bacterium can detect and respond to the chlorinated phloroglucinols produced by neighboring bacterial cells.

Discussion {#s3}
==========

The primary contribution of this work was the discovery of a novel mechanism of co-regulation between secondary metabolite biosynthetic pathways ([Figure 8](#fig8){ref-type="fig"}). This co-regulatory mechanism involves a metabolic intermediate that is transformed through enzymatic activity into a signal regulating gene expression. In contrast to previously described co-regulatory mechanisms involving a metabolic intermediate ([@bib49]; [@bib8]), the metabolic intermediate responsible for coordination of DAPG and pyoluteorin production is not shared by the two biosynthetic pathways. Instead, PG is an intermediate in DAPG biosynthesis and a precursor for formation of signaling molecules that activate expression of pyoluteorin biosynthetic genes ([Figure 8](#fig8){ref-type="fig"}).10.7554/eLife.22835.032Figure 8.Proposed model of metabolic co-regulation between DAPG and pyoluteorin biosynthetic pathways in *P. protegens*.Phloroglucinol (PG) is synthesized by the type III polyketide synthase PhlD in the DAPG biosynthetic pathway, and processed into PG-Cl and PG-Cl~2~ by the halogenase PltM encoded in the pyoluteorin gene cluster. The PG-Cl and PG-Cl~2~ putatively bind to regulator PltR and induce transcription of pyoluteorin biosynthetic genes and prompt production of pyoluteorin. In these two pathways, the final products (DAPG and pyoluteorin), the biosynthesis intermediate (PG) and its derivatives (PG-CL, PG-Cl~2~) can be released and used by bacteria and function as cell-cell communication signals.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.032](10.7554/eLife.22835.032)

The role of antibiotics in cell-cell signaling is now widely recognized ([@bib51]), but the results of this study show that intermediates of antibiotic biosynthesis pathways can also function as, or be converted to, signaling molecules. DAPG and pyoluteorin are known to function as intra- and inter-cellular signals ([@bib7]; [@bib32]; [@bib39]). Here we found that the chlorinated phloroglucinols PG-Cl and PG-Cl~2~ function as intra- and inter-cellular signaling compounds. When added to the culture medium, these compounds can induce expression of pyoluteorin biosynthetic genes in *P. protegens* Pf-5 ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). By co-culturing mutants of Pf-5 with deficiencies in *phlD* and *pltM*, we also showed that PG, PG-Cl and PG-Cl~2~ could be released from the producing cells and used by neighboring cells to induce the production of pyoluteorin ([Table 1](#tbl1){ref-type="table"}, [Figure 7](#fig7){ref-type="fig"}). These results support and extend those from a previous report showing that PG can serve as an intra- and inter-cellular chemical messenger, influencing the expression of pyoluteorin biosynthetic genes as well as hundreds of other genes with diverse functions in *P. protegens* Pf-5 ([@bib10]). Therefore, it appears that the final products DAPG and pyoluteorin, the biosynthetic intermediate PG, and its derivatives PG-Cl and PG-Cl~2~ all serve as signals influencing gene expression, the production of antibiotics, and the antimicrobial activity of *P. protegens* ([Figure 8](#fig8){ref-type="fig"}). The signaling roles of small molecules released as intermediates, derivatives, or end products of antibiotic biosynthesis pathways are likely to be more consequential than previously recognized.

Activation of pyoluteorin biosynthetic genes requires PltR ([@bib7]; [@bib28]) ([Figure 1](#fig1){ref-type="fig"}), the pyoluteorin pathway-specific positive regulator belonging to the LysR family. LysR regulators typically require a signal for activity, and the signal is commonly an intermediate or product of the regulated gene cluster ([@bib31]). Pyoluteorin has been proposed to be the signal of PltR ([@bib28]). However, our data indicate that the signaling effect of pyoluteorin relies on the presence of PG ([Figure 2](#fig2){ref-type="fig"}), which is converted to PG-Cl and PG-Cl~2~ ([Figure 3](#fig3){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Despite our exhaustive attempts, we were not able to purify the PltR protein to evaluate whether or not PG-Cl or PG-Cl~2~ binds to PltR in vitro (data not shown). Nevertheless, based on our data that PG-Cl and PG-Cl~2~ are required for induction of the pyoluteorin biosynthetic genes ([Figure 6](#fig6){ref-type="fig"}), and *pltR* is required for the signaling action of PG-Cl and PG-Cl~2~ in both *P. protegens* Pf-5 ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}) and *P. fluorescens* SBW25 ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), we speculate that that PG-Cl and PG-Cl~2~, rather than pyoluteorin, are signals required for the activity of PltR.

An interesting question is why DAPG and pyoluteorin production are so intricately enmeshed? *P. protegens* can occupy different environments, including the soil, plant surfaces, and insects, and interact with different organisms including bacteria, fungi, protozoa, and insects ([@bib7]; [@bib21]; [@bib25]; [@bib16]; [@bib30]). Both DAPG and pyoluteorin contribute to the antagonism of *P. protegens* against a range of bacteria, fungi, and oomycetes ([@bib37]; [@bib22]) and both facilitate the bacterium's establishment in fungal tissues, such as basidiocarps of the button mushroom *Agaricus* spp. ([@bib16]). However, the sensitivity of a specific organism to these two antibiotics can be different. For example, pyoluteorin is twenty times more toxic than DAPG to the growth of *E. amylovora* ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Furthermore, these two compounds also have distinct ecological roles. For example, DAPG but not pyoluteorin exhibits toxicity to the amoeba *Acanthamoeba castellanii* ([@bib20]). Therefore, natural situations may exist in which it could be more advantageous to produce one compound versus the other. Additionally, antibiotic biosynthesis is associated with metabolic costs. The coordinated production of pyoluteorin and DAPG may be a mechanism for the bacterium to balance metabolic cost against the benefits conferred by production of the two antibiotics. In short, metabolic co-regulation may enable bacteria to activate the production of one antibiotic to combat certain competitors or predators or to occupy specific habitats, while reducing the metabolic burden on the cell by repressing the production of a second compound.

In summary, this study demonstrated that PG, an intermediate in the DAPG biosynthetic pathway, is converted into PG-Cl and PG-Cl~2~, which serve as signals activating expression of pyoluteorin biosynthetic genes. We also showed that PG-Cl and PG-Cl~2~ can be released from and sensed by bacteria to regulate antibiosis against a bacterial pathogen, indicating that these metabolites function as cell-cell communication signals. Many questions remain related to the co-regulation of the DAPG and pyoluteorin biosynthesis pathways. Membrane receptors recognizing the various signaling compounds (DAPG, pyoluteorin, PG, PG-Cl and PG-Cl~2~) have not been identified, but are likely needed to facilitate uptake of these molecules across the bacterial membrane. PG-Cl and PG-Cl~2~ are now known to be responsible for the previously described activation of the pyoluteorin biosynthesis by nanomolar concentrations of PG, but these compounds do not appear to mediate the repression of pyoluteorin production by higher (micromolar) concentrations of PG ([@bib24]). The mechanism(s) involved in inhibition of pyoluteorin production by PG remain unknown. Here, we report a novel mechanism of co-regulation that is responsible for only one aspect of the complex and intricate co-regulation of two secondary metabolites in *P. protegens*. Our results highlight the diversity of mechanisms involved in metabolic co-regulation in bacteria and provide an unprecedented example of co-regulation between separate biosynthetic pathways in which the intermediate of one pathway functions as a precursor of the signal(s) activating the biosynthesis of a second pathway.

Materials and methods {#s4}
=====================

Strains, plasmids, primers, culture conditions and chemical compounds {#s4-1}
---------------------------------------------------------------------

The bacterial strains and plasmids used in this study are listed in [Table 2](#tbl2){ref-type="table"}. The sequences of oligonucleotides used in this study are listed in [Table 3](#tbl3){ref-type="table"}.10.7554/eLife.22835.033Table 2.Bacterial strains and plasmids used in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.22835.033](10.7554/eLife.22835.033)Strains and plasmidsGenotype and relevant characteristics\*Reference or sourceStrains*P. protegens*LK099Wild-type Pf-5([@bib19])JL4928Δ*pltA*Δ*phlD*This studyLK269Δ*pltA*Δ*phlD*Δ*pltR*This studyLK270Δ*pltM*This studyLK024Δ*phlD*([@bib24])LK293Δ*pltM*Δ*pltR*This studyLK397Δ*phlD*Δ*pltM*This studyLK096Δ*pltA*Δ*phlA*([@bib16])LK403Δ*phlA*Δ*pltM*This studyLK413Δ*phlA*Δ*phlD*Δ*pltA*This study*P. fluorescens* SBW25SBW25 is a member of the *P. fluorescens* group but does not contain the *phl* or *plt* gene clusters([@bib44])*E. coli*BL21(DE3)*omp*T *hsd*S~B~ (r~B~^−^m~B~^−^) *gal dcm*NEBS17-1*recA pro hsdR*^-^M^+^ RP4 2-Tc::Mu-Km::*Tn*7 Sm^r^ Tp^r^([@bib45])**Plasmids**pEX18TcGene replacement vector with MCS from pUC18, *sacB*^+^ Tc^r^([@bib18])p18Tc-ΔpltMpEX18Tc containing *pltM* with an internal deletion of 1345 bpThis studypPROBE-NTpBBR1 containing promoterless *gfp*, Km^r^([@bib33])pRL-gfppPROBE-NT containing *pltR* as well as the intergenic region between *pltR* and *pltL* including the promoter of *pltL* fused with a promoterless *gfp*This studypMRL-gfppPROBE-NT containing *pltM* and *pltR* as well as the intergenic region between *pltR* and *pltL* including the promoter of *pltL* fused with a promoterless *gfp*This studypL-gfpCalled ppltL-gfp previously. Contains the intergenic region between *pltR* and *pltL* including the promoter of *pltL* fused with a promoterless *gfp*([@bib50])pME6010pACYC177-pVS1 shuttle vector, Tc^r^([@bib15])pME6010-pltMpME6010 containing *pltM*, which is expressed from the constitutive promoter *Pk*This studypET28a(+)Protein overexpression vectorNovagenpET28a-PltMpET28a containing *pltM*, used for overexpression of the PltM proteinThis studypET28a-SsuEpET28a containing *ssuE*, used for overexpression of the SsuE proteinThis study[^4]10.7554/eLife.22835.034Table 3.Sequences of oligonucleotides used in this study**DOI:** [http://dx.doi.org/10.7554/eLife.22835.034](10.7554/eLife.22835.034)OligonucleotidesDNA sequences\*pltR UpF-XbaGAGAGG[TCTAGA]{.ul}AGTGGAGTCTGGTCATCAAGpltR UpRGCTCTTGTCTTGTAGTCTTCCTGTTTCGGAGAApltR DnFAACAGGAAGACTACAAGACAAGAGCCAGACATCpltR DnR-XbaGGTGTG[TCTAGA]{.ul}GTGAAGAATGAGCAGGTGTCpltM-F1AT[GGTACC]{.ul}CTGCATTTCGATACCGCpltM-R1ATA[GAATTC]{.ul}GGCGGACGGGTGGATCpltMRL-F1AGCGATTTCGATCTTCATCCCCpltM-up-ovlpGAAGCGGCGACACCGGATCCAATCGTTTCATCCpltM-dn-ovlpGGATGAAACGATTGGATCCGGTGTCGCCGCTTCpltRfAT[GGTACC]{.ul}AAGGATTTAGGAATGAAGGCpltM 5\'primerGTCATA[CATATG]{.ul}AATCAGTACGACGTCATTATCpltM 3\' primerCAGTGC[CTCGAG]{.ul}TCAGACTTTGAGGATGAAACGssuE 5\' primerGGAGAG[CATATG]{.ul}CGTGTCATCACCssuE 3\' primerGTA[AAGCTT]{.ul}TTACGCATGGGCATTpltM 3\' primer3ATA[GGATCC]{.ul}GGCCCCGGGCATCACTCAGpltRrTAT[AAGCTT]{.ul}TTCAGCCCGGACTTCGCGAGGgfp-plt-r1AT[GGTACC]{.ul}ATAGACGTACGCTCCTGC[^5]

*P. protegens* Pf-5 and derivatives, *P. fluorescens* SBW25, and *Erwinia amylovora* were cultured at 27°C on King's Medium B agar, Nutrient Agar (Becton, Dickinson and Company, Sparks, MD) supplemented with 1% glycerol (NAGly) or Nutrient Broth (Becton, Dickenson and Company) supplemented with 1% glycerol (NBGly). Liquid cultures were grown with shaking at 200 r.p.m.

PG was purchased from Sigma-Aldrich (St. Louis, MO, USA), MAPG was purchased from Sigma Aldrich Chemie GmbH (Schnelldorf, Germany), and DAPG was purchased from Toronto Research Chemicals (North York, Canada). Chlorinated phloroglucinols PG-Cl, PG-Cl~2~ and PG-Cl~3~ were purchased from Synthon-Lab (St. Petersburg, Russia). All compounds were \>99% pure, as determined by HPLC, and were solubilized in methanol.

Construction of Pf-5 mutants and derivative strains {#s4-2}
---------------------------------------------------

The Δ*pltA*Δ*phlD* mutant was made by sequentially deleting *phlD* and *pltA* genes from the chromosome of wild-type *P. protegens* Pf-5. To delete *phlD* from the chromosome of Pf-5, a *phlD* deletion construct made previously ([@bib24]) was transferred into strain *E. coli* S17-1 and used to delete 888 bp from the *phlD* gene in the chromosome of Pf-5 using a previously described protocol ([@bib24]). To further delete *pltA*, a *pltA* deletion construct made previously ([@bib16]) was used to delete 275 bp from the *pltA* gene in the chromosome of Pf-5. The deletion of *phlD* and *pltA* was confirmed by PCR and subsequent DNA sequencing.

To delete *pltR* from the chromosome of Pf-5, two DNA fragments flanking the *pltR* gene were PCR amplified using the oligonucleotide pair pltR UpF-Xba/pltR UpR and pltR DnR-Xba/pltR DnF ([Table 3](#tbl3){ref-type="table"}). These two fragments were fused together by PCR and digested using XbaI to generate a 1325 bp DNA fragment containing *pltR* with a 925 bp internal deletion. This DNA fragment was ligated to pEX18Tc to create construct p18Tc-ΔpltR. This deletion construct was introduced into the Δ*pltA*Δ*phlD* mutant to make the Δ*pltA*Δ*phlD*Δ*pltR* triple mutant. The deletion of *pltR* was confirmed by PCR and subsequent DNA sequencing.

To delete *pltM* from the chromosome of Pf-5, two DNA fragments flanking the *pltM* gene were PCR amplified using the oligonucleotide pair pltMRL-F1/pltM-up-ovlp and pltM-dn-ovlp/pltRf. These two fragments were fused together by PCR and digested using EcoRI and KpnI to generate a 1120 bp DNA fragment containing *pltM* with a 1345 bp internal deletion. This DNA fragment was ligated to pEX18Tc to create construct p18Tc-ΔpltM. The construct p18Tc-ΔpltM was transferred into strain *E. coli* S17-1 and used to delete 1345 bp from the *pltM* gene in the chromosome of Pf-5. The deletion of *pltM* from Pf-5 was confirmed by PCR and subsequent DNA sequencing.

To complement the Δ*pltM* mutant, a 1661 bp DNA fragment containing *pltM* was PCR amplified using oligonucleotides pltM-F1 and pltM-R1. This PCR product was digested by KpnI and EcoRI and ligated downstream of the constitutively expressing promoter (P*k*) of the kanamycin resistance gene in pME6010 to make the complementation construct pME6010-pltM. The plasmid pME6010-pltM was transferred into Pf-5 derivatives by bi-parental mating ([@bib24]).

Construction of protein overexpression constructs {#s4-3}
-------------------------------------------------

For heterologous expression in *Escherichia coli*, the *pltM* coding sequence was PCR amplified using oligonucleotides pltM 5'primer and pltM 3'primer. The PCR product was digested with NdeI and XhoI, and ligated to the expression vector pET28a(+) to create the expression construct pET28a-PltM, in which *pltM* was expressed with a N-terminal fused 6X His Tag. Similarly, for SsuE, the *ssuE* coding sequence was PCR amplified using *E. coli* K12 genomic DNA as a template, and oligonucleotides ssuE 5'primer and ssuE 3'primer. The PCR product was digested with NdeI and HindIII and ligated to the expression vector pET28a(+) to create the expression construct pET28a-SsuE, in which SsuE was expressed with a N-terminal fused 6X His Tag.

Construction of transcriptional reporter constructs {#s4-4}
---------------------------------------------------

For reporter constructs, three variants of *pltL*::GFP were constructed. pL-gfp contains the promoter of *pltL* fused to a promoterless *gfp* ([@bib50]). The construct pRL-gfp includes the entire *pltR* coding sequence and the predicted promoter sequence of *pltL*. To make this construct, a 1600 bp DNA fragment was PCR amplified using oligonucleotides pltRr and gfp-plt-r1. The resultant PCR fragment was digested with HindIII and KpnI and ligated to pPROBE-NT to create the construct pRL-gfp. The construct pMRL-gfp contains *pltM* and *pltR* and the promoter region of *pltL* fused to a promoterless *gfp*. To make this construct, a 3050 bp DNA fragment was PCR amplified using pltM 3\'primer3 and gfp-plt-r1. The resultant PCR fragment was digested with BamHI and KpnI and ligated to pPROBE-NT to create the construct pMRL-gfp.

GFP quantification {#s4-5}
------------------

Strains *P. protegens* Pf-5 and *P. fluorescens* SBW25 containing *gfp*-based reporter plasmids were cultured overnight in NBGly at 27°C with shaking. The cells were washed once with fresh NBGly and used to inoculate 5 ml NBGly to an optical density of 600 nm (OD~600~) of 0.01. Five microliters of purified compounds at various concentrations (pyoluteorin, PG, and chlorinated derivatives of PG) or extracts (described below) were added to the 5 ml cultures. The cultures were incubated for 20 hr at 27°C with shaking. The OD~600~ was measured to monitor growth of the bacteria. The green fluorescence of bacteria was monitored using a 96-well plate reader (Tecan Infinite 200Pro, Männedorf, Switzerland) by measuring emission at 535 nm with an excitation at 485 nm. For each measurement, the green fluorescence value was divided by the corresponding OD~600~ to determine the relative GFP level. The green fluorescence emitted by cells of wild-type strains without *gfp* reporter constructs was determined and used for background correction.

Protein purification and in vitro activity assay {#s4-6}
------------------------------------------------

The expression plasmids pET28a-PltM and pET28a-SsuE were transformed into *E. coli* BL21 (DE3). Cells were grown in LB broth, supplemented with 50 mg/ml kanamycin, at 37°C to an OD~600~ of 0.5, induced with 0.4 mM IPTG, and grown for an additional 12 hr at 20°C. The cells were harvested and suspended in Tris-NaCl buffer (20 mM Tris pH 7.4/200 mM NaCl), and lysed by sonication. The His-tagged proteins were purified using the Ni-NTA Purification System (Invitrogen) under native purification conditions. Purified PltM and SsuE were dialyzed in Tris-NaCl-Glycerol buffer \[20 mM Tris pH 7.4/200 mM NaCl/10% (vol/vol) glycerol\]. The protein concentrations were determined using a *DC* Protein Assay (Bio-Rad) and proteins were stored at −80°C.

To test the catalytic activity of PltM, 20 μl of 56 µM PltM, 50 μl of 21 µM SsuE, 4 μl of 10 mM FAD, 10 μl of 100 mM NADPH, and 10 μl of 10 mM PG were added to 106 μl of Tris-NaCl buffer (20 mM Tris pH 7.4/200 mM NaCl). Five additional reactions were also set up, with one of the five components replaced by an equivalent volume of the Tris-NaCl buffer in each reaction. The mixtures were incubated for 3 hr at 25°C and extracted three times with ethyl acetate. The ethyl acetate extracts were dried under vacuum at room temperature and dissolved in 200 μl methanol. A volume of 5 μl from each methanol solution was added to *P. fluorescens* SBW25 containing the reporter plasmid pRL-gfp to determine the signaling activity of each reaction product. For LCMS analysis, the reactions were concentrated to dryness and dissolved in 100 μl methanol and 10 μl were analyzed as described below.

Quantification of MAPG, DAPG, and pyoluteorin {#s4-7}
---------------------------------------------

Pf-5 and derivative strains were inoculated at a starting OD~600~ of 0.01 in 5 ml NBGly and cultured for 24 hr. Four milliliters of the culture supernatant were extracted twice with ethyl acetate, then subsequently dried under vacuum, and suspended in methanol. The culture extracts were analyzed by high-performance liquid chromatography (HPLC) to quantify production of MAPG, DAPG, and pyoluteorin as described below.

To quantify the production of MAPG, DAPG and pyoluteorin by Pf-5 and derivatives, HPLC analyses were accomplished using an Agilent 1100 HPLC instrument, which consisted of a quaternary pump, vacuum degasser, autosampler, column thermostat (set to 30°C), and diode array detector. Separation was achieved using a Luna C18 column (4.6 × 150 mm, 5 μm, Phenomenex, Torrance, CA) with a flow rate of 1 ml/min where line A was water + 0.1% (vol/vol) formic acid, and line B was acetonitrile + 0.1% (vol/vol) formic acid with the following program. The column was pre-equilibrated in 90% A/10% B, and upon injection this composition was held for 2 min. The composition of the mobile phase was then changed to 0% A/100% B over 28 min using a linear gradient. This composition was held for 6 min then changed to 90% A/10% B over 2 min. The column was equilibrated in 90% A/10% B for 6 min prior to the next injection. Under these chromatographic conditions, MAPG eluted at 12.1 min, pyoluteorin eluted at 15.1 min, and DAPG eluted at 18.1 min. The HPLC was operated with and data viewed withChemStation (version B.04.03, Agilent, Santa Clara, CA). Quantification was performed by integrating the area under the curve at 300 nm and comparing with a standard curve prepared by injection of purified pyoluteorin, MAPG, and DAPG. Data were processed with GraphPad Prism (GraphPad Software, San Diego, CA).

Identification of chlorinated phloroglucinols {#s4-8}
---------------------------------------------

For LCMS analysis of crude culture extracts of the wild-type Pf-5 and the Δ*pltM* mutant, these two strains were grown for 20 hr in 500 ml NBGly at 27°C with shaking. The supernatants of the cultures were extracted twice with ethyl acetate (250 ml). The extracts were concentrated in vacuo to dryness. The dried extracts were dissolved in 50 µl methanol and then diluted to 400 µl with water. The large amount of precipitate formed was removed by centrifugation (15,000 *x g*, 60 min, 10°C), and 10 µl of the clear supernatant were analyzed by LCMS as described below.

LCMS analysis was performed using a Agilent 1260 HPLC (consisting of degasser, quaternary pump, autosampler, and diode array detector) upstream of a 6230 ESI-TOF operated in negative ionization mode with the following parameters: Mass range, 100--3200 m/z in profile mode; Gas temperature, 350°C; Drying gas, 10 L/min; Nebulizer, 40 psig; Capillary voltage, 3500 V; Fragmentor, 100 V; Skimmer, 65 V; OCT 1 RF Vpp, 750 V; Acquisition rate, five spectra/sec; Time, 200 ms/spectrum; Transients/spectrum, 1902). The synthesized authentic compounds PG-Cl, PG-Cl~2~ and PG-Cl~3~ were used as standards for comparisons in the analysis. Separation was achieved with an Extend C18 column (2 × 100 mm, 3 µm, Agilent) at a flow rate of 0.2 ml/min. The column was pre-equilibrated in 98% A/2% B, where A was water + 0.1% (vol/vol) formic acid and B was acetonitrile + 0.1% (vol/vol) formic acid. This composition was held for 1 min and then changed to 100% B over 30 min using a linear gradient. After that, the composition was held for an additional 12 min and the composition was returned to 98% A/2% B over 2 min. The column was equilibrated at 98% A/2% B for 12 min prior to injection of the next sample. The LCMS was operated with and data were viewed using MassHunter (version B.04.03, Agilent, Santa Clara, CA).

Culture extracts from the wild-type Pf-5 were also fractioned by semi-preparatory HPLC and signal activity of the fractions was tested by the reporter strain *P. fluorescens* SBW25 containing pRL-gfp. The wild-type Pf-5 was cultured for 20 hr in 500 ml NBGly at 27°C with shaking before being extracted twice with ethyl acetate (250 ml). The dried extracts were dissolved in 1 ml methanol and mixed with 1 ml water. The concentrated extracts were separated by semi-preparatory HPLC using a PuriFlash Pf450 (Interchim Inc., Los Angeles, CA). Separation was achieved using a Purisphere C18 column (10 × 150 mm, 10 µm, Interchim Inc.) at a flow rate of 2 ml/min. The column was pre-equilibrated in 90% A/10% B, where A was water and B was methanol. This composition was held for 2 min and then increased to 100% B over 40 min using a linear gradient and pure methanol was flown over the column for an additional 9 min. The effluent from the pump was collected directly into a 96-deep well plate in 1 min time slices after discarding the first 3 min to waste. Five microliters from each well were tested using SBW25 (pRL-gfp) and fluorescence was observed as described above.

To obtain sufficient levels of signaling molecules for LCMS analysis, the Δ*gacA* mutant of Pf-5 containing pME6010-pltM was cultured in three flasks, each containing 1000 ml NBGly amended with 12.5 µg/ml PG. The cultures were incubated for 20 hr at 27°C with shaking before being extracted twice with ethyl acetate (300 ml). Extracts were concentrated in vacuo to dryness. The dried extracts from the three replicate cultures were combined and dissolved in 1.5 ml methanol. A portion (200 µl) was diluted with 1.8 ml of water. The concentrated extracts were fractioned by semi-preparatory HPLC and the signal activity of the fractions were tested using SBW25 (pRL-gfp) as described above. The fractions with the highest signal activity were concentrated to dryness separately and analyzed by LCMS along with synthesized standards including PG-Cl, PG-Cl~2~ and PG-Cl~3~ as described above.

Antibiosis assay {#s4-9}
----------------

Antibiosis of Pf-5 and derivatives against the plant pathogen *E. amylovora* was determined on NAGly. *E. amylovora* was cultured overnight in 5 ml NBGly at 27°C with shaking, and 80 μl of the cultures were inoculated into 8 ml melted NAGly (45°C), and poured over solidified NAGly in a Petri plate. This two-layer plate was air-dried with the lid open for 1 hr to solidify the agar and remove extra moisture. The Δ*phlA*Δ*pltM* mutant and the Δ*phlA*Δ*phlD*Δ*pltA* mutant were cultured overnight in 5 ml NBGly at 27°C with shaking. The cells were washed once with fresh NBGly and used to make a bacterial suspension with an OD~600~ of 0.05. For co-culture, cells of the two mutants were combined in a 1:1 ratio for a total OD~600~ of 0.05. Two microliters of the bacterial suspensions were used to inoculate three two-layer plates and incubated for 3 d at 27°C. The agar medium with the Pf-5 strains in the center was cut from the plate and concentrations of DAPG and pyoluteorin in the agar were quantified as follows. Bacterial cells were carefully removed from the agar using Kimwipe. The agar was weighed, sliced into small pieces and immersed for 30 min in sterilized water before extracting twice with ethyl acetate. The extracts were dried and the residue was dissolved in 20 μl methanol and analyzed by HPLC as described above.

Statistical analysis {#s4-10}
--------------------

Statistical analyses were performed by ANOVA and Tukey multiple comparison using SPSS statistics 20 (SPSS Inc., Chicago, IL). All replicates in this study were biological replicates. Sample sizes are indicated in the figure legends. All data are presented as mean ± standard derivation.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Novel mechanism of metabolic crosstalk coordinates the biosynthesis of secondary metabolites in *Pseudomonas protegens*\" for consideration by *eLife*. Your article has been favorably evaluated by Richard Losick (Senior Editor) and three reviewers, one of whom, Jon Clardy (Reviewer \#1), is a member of our Board of Reviewing Editors. The following individuals involved in review of your submission have agreed to reveal their identity: Pierre Stallforth (Reviewer \#2) and Sarah O\'Connor (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript reports an interesting case in which two antibiotic biosynthesis pathways in *Pseudomonas protegens* are linked through having an intermediate for one be modified by an enzyme in the second to produce a third molecule that up-regulates the biosynthesis of the second antibiotic. The two antibiotics -- diacylphloroglucinol (DAPG) and pyoluteorin (PLT) -- are well known and have distinct if overlapping activities. This study reports that phloroglucinol (PG), a precursor of DAPG, is modified by a chlorinase in the PLT biosynthetic pathway to produce chlorinated versions of PG, PG-Cl and PG-Cl~2~. The chlorinated PGs function as positive regulators of PLT biosynthesis, and are themselves antibiotics. The latter finding is not surprising, as they resemble carbolic acid -- an antibiotic going back to Joseph Lister. The study is well done, and the results are unexpected.

Essential revisions:

The reviewers were uniformly enthusiastic about publishing your article after some revision. Major issues that need to be addressed are summarized below, along with the individual review of reviewer \#3.

1\) Enhanced mechanistic analysis of the co-regulation including the difference/similarity of phlD and pltD, apparently redundant enzymes for PG production. A mechanistic analysis would be facilitated by using \"co-regulation\", which is the much more informative description used in the impact statement, rather than \"crosstalk\", which following its more common definition of \"components of different signal transduction pathways affecting one another\", is inappropriate.

2\) The structural analysis of PG-Cl and PG-CL~2~ are not up to the usually accepted standards for establishing the structures of new molecules. It should be relatively easy to provide the additional data.

3\) Suggest that the title be modified to: Metabolic co-regulation coordinates the biosynthesis of secondary metabolites in *Pseudomonas* protegens.

*Reviewer \#3:*

This manuscript demonstrates how a *Pseudomonas* species uses crosstalk between the two natural product pathways, DAPG and pyoluteorin, to control the regulation of these natural product biosynthesis pathways. While metabolic crosstalk has been previously observed on many other occasions, the authors convincingly demonstrate how this is an unusual and unprecedented mechanism. The authors use an assay based on the transcription of a reporter protein to identify the two signaling molecules responsible for the crosstalk, in this case two chlorinated derivatives of a biosynthetic intermediate of the DAPG biosynthetic pathway. Overall, this is an elegant study that shows an unusual mechanism of crosstalk. I believe that it is appropriate for the broad readership of *eLife*.

I have the following comments below:

In [Figure 5](#fig5){ref-type="fig"} only the mass of the products is shown, which is not sufficient for structural characterization. The authors should show that these two isolated products co-elute with authentic standards, and should also show that these isolated products have the same mass and retention time of the products of the in vitro reaction with PG (which is only demonstrated by a bar graph in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). High resolution mass spectra are very easy to obtain and are standard for molecular characterization and should also be included. These are fairly simple experiments and will provide much more convincing data that the structures are as indicated in [Figure 4](#fig4){ref-type="fig"}.

The authors state (subsection "*pltM* is necessary and sufficient for the *PltR*-mediated activation of *pltL* expression by PG", first paragraph) \"Moreover, *pltM* and *pltR* share similar transcriptional profiles (Clifford et al. 2015).\" I was curious how the expression profile of *pltM* compared to rest of the *plt* and *phb* clusters. Can the authors make a brief comment on this, with the data that is currently available (i.e., the data in Clifford et al.)?

In the legend of [Figure 6](#fig6){ref-type="fig"}, the authors should indicate at what time point during the culture period these data points were taken.
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Author response

*Essential revisions:*

*The reviewers were uniformly enthusiastic about publishing your article after some revision. Major issues that need to be addressed are summarized below, along with the individual review of reviewer \#3.*

*1) Enhanced mechanistic analysis of the co-regulation including the difference/similarity of phlD and pltD, apparently redundant enzymes for PG production.*

We think there was some confusion surrounding this issue because *pltD* (gene locus ID: PFL_2790) is not mentioned in this manuscript and has no role in PG production. Previous studies showed that *phlD* (gene locus ID: PFL_5957), which encodes a type III polyketide synthase, is responsible for PG biosynthesis: heterologous expression of *phlD* led to an accumulation of PG in *Escherichia coli* cultures, and purified PhlD converted malonyl-coA into PG in vitro(Achkar et al. 2005). More importantly, *phlD* is the only gene for PG production of Pf-5, as a knockout of the *phlD* gene completely abolishes PG production (Kidarsa et al. 2011). To address this, we reiterated in the revised manuscript (page 4, line 66-67), that *phlD* is necessary for PG production.

*A mechanistic analysis would be facilitated by using \"co-regulation\", which is the much more informative description used in the impact statement, rather than \"crosstalk\", which following its more common definition of \"components of different signal transduction pathways affecting one another\", is inappropriate.*

Thank you for this suggestion. We changed all uses of "crosstalk" to "co-regulation".

*2) The structural analysis of PG-Cl and PG-CL~2~ are not up to the usually accepted standards for establishing the structures of new molecules. It should be relatively easy to provide the additional data.*

We added the following additional evidence to support the structural analysis of PG-Cl and PG-Cl~2~.

First, by comparison to the synthesized authentic compounds PG-Cl and PG-Cl~2~, we detected PG- Cl and PG-Cl~2~ in the culture extracts of a Δ*gacA* mutant of Pf-5 containing a plasmid-borne *pltM*. These data were added as revised [Figure 4](#fig4){ref-type="fig"} in the revised manuscript.

Second, by comparison to the synthesized PG-Cl and PG-Cl~2~, we detected these two compounds in the extracts of in vitro full reaction containing substrate PG, halogenase PltM and it co-factors, but not in the reaction without PltM. These data were added as [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} in the revised manuscript.

*3) Suggest that the title be modified to: Metabolic co-regulation coordinates the biosynthesis of secondary metabolites in Pseudomonas protegens.*

Thank you. We changed the title to "Novel mechanism of metabolic co-regulation coordinates the biosynthesis of secondary metabolites in *Pseudomonas protegens*" as suggested by the Editor. We kept the "Novel mechanism" because of the novelty of the mechanism of co-regulation revealed in this study.

*Reviewer \#3:*

*\[...\] I have the following comments below:*

*In [Figure 5](#fig5){ref-type="fig"} only the mass of the products is shown, which is not sufficient for structural characterization. The authors should show that these two isolated products co-elute with authentic standards, and should also show that these isolated products have the same mass and retention time of the products of the in vitro reaction with PG (which is only demonstrated by a bar graph in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). High resolution mass spectra are very easy to obtain and are standard for molecular characterization and should also be included. These are fairly simple experiments and will provide much more convincing data that the structures are as indicated in [Figure 4](#fig4){ref-type="fig"}.*

We added the requested data to support the structural analysis of PG-Cl and PG-Cl~2~. We showed that PG- Cl and PG-Cl~2~ in the HPLC fraction 21 and 26 of culture extractions from the cultures of a Pf-5 derivative strain co-eluted with the synthesized PG-Cl and PG-Cl~2~ ([Figure 4](#fig4){ref-type="fig"} in the revised manuscript).

Furthermore, by comparing the structures determined from extracts to those for the authentic compounds, we confirmed that PG-Cl and PG-Cl~2~ are present in the "full in vitro reaction" containing purified PltM and PG ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} in the revised manuscript). These data have been added to the revised manuscript.

*The authors state (subsection "pltM is necessary and sufficient for the PltR-mediated activation of pltL expression by PG", first paragraph) \"Moreover, pltM and pltR share similar transcriptional profiles (Clifford et al. 2015).\" I was curious how the expression profile of pltM compared to rest of the plt and phb clusters. Can the authors make a brief comment on this, with the data that is currently available (i.e., the data in Clifford et al.)?*

The expression profile of *pltM, pltR* and the other genes in the pyoluteorin gene cluster was summarized from previous study (Clifford et al. 2015) and this information and supporting data were added in the revised manuscript ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

*In the legend of [Figure 6](#fig6){ref-type="fig"}, the authors should indicate at what time point during the culture period these data points were taken.*

Thank you. GFP expression was tested at 20 hours after inoculation and the metabolites were extracted and tested at 24 hours after inoculation. This information has been added in the legend of [Figure 6](#fig6){ref-type="fig"} of the revised manuscript.

[^1]: \*The mutants were cultured for 3 d on a NAGly plate to determine production of secondary metabolites, and for 20 hr in NBGly broth to determine expression of *pltL::gfp* from the reporter construct pL-gfp ([Figure 1E](#fig1){ref-type="fig"}). The co-culture was prepared by mixing the two mutants at a 1:1 ratio.

[^2]: **^†^**PG, PG-Cl or PG-Cl~2~ was amended in the mutant cultures to test their influences on the expression of *pltL::gfp*. The concentrations of the tested compounds are shown in parenthesis.

[^3]: ^‡^Secondary metabolites were extracted from the agar plate and the concentrations of DAPG and pyoluteorin were determined by HPLC. Expression of *pltL::gfp* was monitored and recorded as relative GFP (fluorescence of GFP divided by OD~600~). ^§^The Δ*phlA*Δ*pltM* mutant, but not the Δ*phlA*Δ*phlD*Δ*pltA* mutant, contains pL-gfp in the co-culture. ^¶^The Δ*phlA*Δ*phlD*Δ*pltA* mutant, but not the Δ*phlA*Δ*pltM* mutant, contains pL-gfp in the co-culture. Data are presented as mean ± standard derivation. Mean values are calculated from three biological replicates. BD = below detection. NT = not tested.

[^4]: \*Sm^r^, streptomycin resistance; Tp^r^, trimethoprim resistance; Tc^r^, tetracycline resistance; Km^r^, kanamycin resistance.

[^5]: \*Restriction sites used for cloning are underlined in oligonucleotides.
